PharmaBoardroom

Taming the ‘Wild West’ of CBD

Monica Weldon looks at the history of medicinal CBD, its current usages in the USA, and why robust scientific research on its efficacy need to be…

Scaling Healthcare’s Digital Transformation with AI

Digital marketing expert Buck Dossey expounds the importance of soliciting user data to improve patient experiences and the ways in which AI can be…

Change is Coming for Healthcare

Aditya Bhattacharji examines whether current healthcare models are truly fit for purpose and how healthcare is becoming a more politicised issue…

5 Top European Mid-Cap CEOs To Know

Bringing together insights from the heads of some of Europe's most prominent mid-cap pharma firms. The leaders of Ipsen, Genmab, Pierre Fabre, Esteve…

Comprehensive Access to Medicines should be the Priority for…

Canada is the only developed country with a universal healthcare system that does not provide universal coverage of prescription drugs. With a new…

The Medical Cannabis Investment Landscape

David H. Crean, managing director for Objective Capital Partners, highlights the progress that has been made over the past year in investments in…

Is CNS the Next Oncology?

Cerecin's Charles Stacey looks at the large unmet medical need in diseases of the central nervous system (CNS), the looming socioeconomic burden that…

Transitioning Pharma’s Data Supply Chain into the 21st Century

An examination of the evolution of the pharma data supply chain and the vital importance of establishing trust with patients to access complete…

Jessica Federer – Advisor, Hugo Health, USA

Jessica Federer, advisor at Hugo Health and one of the speakers at the upcoming FT US Pharma and Biotech Summit, discusses some of the key trends…

AI in Clinical Trials: Improving Efficiency, Reducing Costs

Paul Bleicher, CEO at OptumLabs, and one of the speakers at the FT US Pharma & Biotech Summit on May 14, shares insights on the benefits we will…

USA: The Biosimilars Trade Opportunity

Chip Davis of the Association for Accessible Medicines argues for greater provision for access to affordable medicines – including biosimilars –…

Pharma Must Embrace Real-World Evidence to Remain Competitive

Holmusk’s Nawal Roy highlights the increasing recognition of the value of real-world evidence (RWE) by both innovative pharma companies and drug…

Tagged with OP